Saroja Pharma Industries India Ltd
Chemicals & Petrochemicals | Small Cap
Saroja Pharma Industries India Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Efficiency ratios are also notable, driven by high turnover in fixed assets and inventory. However, liquidity is a concern, with low cash and operating cash flow ratios. Growth metrics present a varied picture, with strong revenue and asset growth offset by a decline in earnings per share. The company's coverage ratios are also weak, reflecting limited ability to cover interest and dividends. These factors suggest that while the company is profitable and growing, it needs to strengthen its short-term financial health and improve earnings efficiency. Future success depends on balancing growth initiatives with sustainable financial practices.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio4.60
- Profitability Ratio9.80
- Efficiency Ratio6.67
- Coverage Ratio4.40
- Solvency Ratio10.00
- Liquidity Ratio4.94
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Saroja Pharma Industries India Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Efficiency ratios are also notable, driven by high turnover in fixed assets and inventory. However, liquidity is a concern, with low cash and operating cash flow ratios. Growth metrics present a varied picture, with strong revenue and asset growth offset by a decline in earnings per share. The company's coverage ratios are also weak, reflecting limited ability to cover interest and dividends. These factors suggest that while the company is profitable and growing, it needs to strengthen its short-term financial health and improve earnings efficiency. Future success depends on balancing growth initiatives with sustainable financial practices.
Overall Valuation Score
P/E RATIO (TTM)
11.08
Industry Median
22.59
Small Cap Median
21.70
P/E RATIO
13.67
P/B RATIO
0.87
Industry Median
1.76
Small Cap Median
1.77
P/S RATIO
0.26
Industry Median
0.89
Small Cap Median
0.88
Others
PEG RATIO
0.00
EV/EBITDA RATIO
4.71
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹35 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates strong growth in revenue and assets, but earnings per share growth is a concern. High growth rates in revenue and assets indicate successful expansion, while negative EPS growth suggests challenges in translating revenue into profits. This mixed performance requires attention to improve profitability alongside growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 51.75 | -9.78 | -18.97 | 32.11 | 30.73 |
| Operating Profit Growth Rate | 61.54 | 29.52 | -5.88 | 8.59 | 37.05 |
| Earnings Per Share (EPS) Growth | -93.08 | -92.85 | -39.34 | 16.89 | 57.42 |
| Asset Growth Rate | 88.69 | 37.59 | 24.51 | 48.85 | 5.56 |
| Net Income Growth Rate | 56.16 | -7.02 | -16.98 | 17.05 | 57.28 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed picture. While capital expenditures are well-managed, adjusted and cash earnings per share are low, and the book value per share is also a concern. The absence of dividends may deter some investors. Overall, these factors indicate areas needing improvement to enhance financial performance and investor appeal.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 57 | 3.66 | 2.2 | 2.57 | 4.05 |
| Cash Earnings Per Share (Cash EPS) | 59.5 | 3.9 | 2.42 | 2.85 | 4.33 |
| Book Value Per Share | 201.5 | 17.55 | 36.6 | 39.2 | 43.22 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0.3 | 3.7 | 0.4 | 0.1 | 11.5 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company exhibits strong profitability, with high gross profit margins, ROCE, ROE, and ROA, indicating efficient operations and effective use of capital. This robust profitability enhances the company's financial stability and attractiveness to investors. This indicates that company is very profitable and is using its capital very efficiently.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.69 | 5.28 | 6.07 | 4.97 | 5.27 |
| Return on Capital Employed (ROCE) | 33.55 | 22.09 | 14.93 | 12.57 | 13.02 |
| Return on Equity (ROE) | 28.29 | 20.83 | 6.01 | 6.57 | 9.37 |
| Return on Assets (ROA) | 13.54 | 12.75 | 9.63 | 7.03 | 9.13 |
| Operating Margin | 3.77 | 5.42 | 6.29 | 5.17 | 5.42 |
| Net Margin | 2.05 | 2.11 | 2.16 | 1.92 | 2.31 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company demonstrates strong efficiency in managing fixed assets and inventory, but struggles with receivables management. High turnover ratios for fixed assets and inventory indicate effective utilization, while longer receivable days suggest potential issues in collecting payments promptly. This mixed performance highlights areas for improvement in working capital management.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 163.62 | 22.61 | 16.2 | 21.41 | 32.22 |
| Inventory Turnover Ratio | 94.83 | 21.91 | 17.89 | 204.24 | 138.63 |
| Receivables Turnover Ratio | 5.25 | 4 | 2.97 | 2.51 | 3.2 |
| Days Sales in Inventory Ratio | 3.85 | 16.66 | 20.4 | 1.79 | 2.63 |
| Receivable Days | 69.52 | 91.25 | 122.9 | 145.42 | 114.06 |
| Capital Turnover Ratio | 9.71 | 6.36 | 2.36 | 3.15 | 2.85 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios suggest a limited ability to cover its interest expenses and equity dividends. While the interest coverage ratio is adequate, the lack of equity dividend coverage is a concern. This situation may limit the company's financial flexibility and attractiveness to investors.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 2.96 | 2.13 | 1.83 | 2.03 | 2.53 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits a strong solvency position, indicating a solid financial structure with low debt levels relative to equity and assets. This provides a stable foundation for future growth and reduces the risk of financial distress. This suggests a financially stable company capable of meeting its long-term obligations.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.3 | 0.35 | 0.15 | 0.08 | 0.3 |
| Debt to Equity Ratio | 0.43 | 0.54 | 0.18 | 0.09 | 0.43 |
| Equity Ratio | 0.7 | 0.65 | 0.85 | 0.92 | 0.7 |
| Debt To Asset Ratio | 0.11 | 0.13 | 0.1 | 0.03 | 0.18 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position indicates challenges in meeting its short-term obligations. While the quick ratio suggests some ability to cover immediate liabilities, the low cash ratio raises concerns about reliance on converting other assets to cash. This mixed performance requires careful monitoring to ensure the company can manage its current liabilities effectively.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.55 | 1.28 | 1.9 | 1.25 | 1.09 |
| Quick Ratio | 1.5 | 0.99 | 1.86 | 1.24 | 1.04 |
| Cash Ratio | 0.03 | 0.03 | 0.03 | 0.01 | 0.02 |
| Operating Cash Flow Ratio | -0.38 | 0.16 | 0.11 | 0.05 | 0.44 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Saroja Pharma Industries India Ltd | 7.47 | 13.67 | Neutral | 3.81 | 4.02 | 1.62 |
| 2 | Sanginita Chemicals Ltd | 7.17 | 62.58 | Undervalued | -6.00 | -3.74 | -10.00 |
| 3 | Yasons Chemex Care Ltd | 5.91 | 22.35 | Neutral | -0.59 | 0.49 | 0.94 |
| 4 | Vadivarhe Speciality Chemicals Ltd | 4.07 | -3.66 | Highly Undervalued | -6.42 | -7.25 | -9.27 |
| 5 | Omkar Speciality Chemicals Ltd | 3.63 | 0.23 | Highly Undervalued | 101.00 | -6.42 | 37.00 |
The management effectiveness of Saroja Pharma Industries India Ltd shows a mixed performance. The company has demonstrated revenue expansion but there are concerns regarding declining ROCE and increasing Debt. The high promoter holding indicates confidence of the promoters in the business.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 73.02% | High promoter holding indicates promoter confidence |
| CONS | ROCE (Mar 2025) | 12.57% | Declining ROCE indicates decreasing efficiency in capital utilization |
| CONS | Borrowings (Mar 2025) | 9.46 Cr | Increasing debt can increase financial risk |
Financial Performance & Growth
Saroja Pharma exhibits mixed financial performance. Sales Growth has fluctuated, with a TTM growth of 33%, but a 3-year compounded sales growth of -1%. Profit growth is also inconsistent, with a 3-year compounded profit growth of -3% and a TTM growth of 17%. OPM has shown slight improvement, hovering around 5-6% in recent quarters.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Sales Growth (%) | 51.75% | -9.78% | -18.97% | 32.58% |
Capital Efficiency & Returns
The company's capital efficiency and returns, indicated by ROCE, show a declining trend. ROCE has decreased from 33.55% in Mar 2022 to 12.57% in Mar 2025. ROE is 8.90%. This decline indicates decreasing efficiency in capital utilization.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| ROCE % | 33.55% | 22.09% | 14.93% | 12.57% |
Financial Health & Prudence
The company's debt management is a concern. Borrowings have increased over the years, with total borrowings rising from 3.02 Cr in Mar 2021 to 9.46 Cr in Mar 2025. The company has not been paying any dividends. The rising debt can increase financial risk.
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Borrowings (Cr) | 3.02 | 6.14 | 10.18 | 5.73 | 9.46 |
Shareholding & Ownership Structure
Promoter holding is consistently high at 73.02%, indicating promoter confidence and alignment with shareholder interests. There is no data available for Institutional Holding (FII/DII).
Saroja Pharma Industries India Ltd. faces moderate risk due to fluctuations in sales growth, and increasing Debt. While the promoter holding is stable, the declining ROCE and increasing Debt raise concerns about long-term financial health and operational efficiency.
Segment performance volatility
Sales growth rates have been inconsistent, ranging from a 51.75% increase in Mar 2022 to a -18.97% decrease in Mar 2024. This high variability in segment performance impacts overall financial stability.
Accounting quality red flags
Material costs consistently account for a high percentage of sales, around 90%, which may indicate limited cost management flexibility or pricing power.
Foreign exchange or interest rate exposure
The company's interest expense has generally increased, from 0.33 Cr in Mar 2021 to 1.41 Cr in Mar 2025. This increase in interest expenses impacts profitability. This rising interest expense increases financial risk.
Regulatory compliance cost trends
Tax percentage has been consistent, around 27-29%, suggesting a stable regulatory environment regarding taxation.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe